Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I

Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I

Bibliographic Details
Main Authors:	Amanda Wilson, Raffaella M. Colzani, Ana Lorena Flores
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Molecular Genetics and Metabolism Reports
Subjects:	Real-world evidence enzyme replacement therapy MPS I Home-based infusion
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214426921000306

Similar Items

The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis
by: Ana Paula Fiuza Funicello Dualibi, et al.

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
by: Roberto Giugliani, et al.
Published: (2017-03-01)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
by: Juan Politei, et al.
Published: (2021-03-01)

Enzyme replacement therapy: efficacy and limitations
by: Daniela Concolino, et al.
Published: (2018-11-01)

Ocular features in mucopolysaccharidosis: diagnosis and treatment
by: Alessandra Del Longo, et al.
Published: (2018-11-01)

The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy
by: Ria Heinrich, et al.
Published: (2023-06-01)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
by: Federico Spataro, et al.
Published: (2022-11-01)

Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
by: Rossella Parini, et al.
Published: (2020-04-01)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
by: Yu-Hone Hsu, et al.
Published: (2017-06-01)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
by: Imke A. M. Ditters, et al.
Published: (2023-05-01)

Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier DS, et al.
Published: (2016-06-01)

Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children
by: Dafne D.G. Horovitz, et al.
Published: (2015-12-01)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
by: Antonio Toscano, et al.
Published: (2023-10-01)

Mucopolysaccharidosis type I - Clinical and genetic characteristics of Romanian patients
by: Alkhzouz Camelia, et al.
Published: (2020-07-01)

Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI
by: Rohit Nagpal, et al.
Published: (2022-09-01)

Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome
by: Daniel C. Julien, et al.
Published: (2020-05-01)

Growth patterns in patients with mucopolysaccharidosis VII
by: Adriana M. Montaño, et al.
Published: (2023-09-01)

Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist
by: Toni Docherty, et al.
Published: (2020-12-01)

Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy
by: Hui Chen, et al.
Published: (2021-11-01)

Cognitive Abilities of Dogs with Mucopolysaccharidosis I: Learning and Memory
by: Lena Provoost, et al.
Published: (2020-02-01)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
by: Shoshana Revel-Vilk, et al.
Published: (2023-09-01)

Telemonitoring of home infusion technology
by: Sonja Jutte
Published: (2010-12-01)

Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population
by: Christine Haller, et al.
Published: (2019-09-01)

Editorial: Cardiac issues in adults with mucopolysaccharidosis
by: Karolina M. Stepien, et al.
Published: (2022-08-01)

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
by: Katherine H. Kim, et al.
Published: (2015-03-01)

The diagnostic journey of patients with mucopolysaccharidosis I: A real-world survey of patient and physician experiences
by: Stefano Bruni, et al.
Published: (2016-09-01)

Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
by: Alia Ahmed, et al.
Published: (2016-06-01)

A model of mucopolysaccharidosis type IIIB in pigs
by: Qiang Yang, et al.
Published: (2018-10-01)

Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI
by: Emine Azak, et al.
Published: (2019-10-01)

Mucopolysaccharidosis: A broad review
by: Ritu Nagpal, et al.
Published: (2022-01-01)

Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII
by: Simon Jones, et al.
Published: (2021-09-01)

A Neonate with Mucopolysaccharidosis Type VII with Intractable Ascites
by: Kana Fukui, et al.
Published: (2023-01-01)

The factors affecting lipid profile in adult patients with Mucopolysaccharidosis
by: Karolina M. Stepien, et al.
Published: (2017-09-01)

Description of the molecular and clinical characteristics of the mucopolysaccharidosis type VII Iberian cohort
by: Antonio Gónzalez-Meneses, et al.
Published: (2021-10-01)

Survey of Pancreatic Enzyme Replacement Therapy Dosing Experiences in Adults with Exocrine Pancreatic Insufficiency
by: Dana M. Lewis, et al.
Published: (2023-08-01)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
by: Hsiang-Yu Lin, et al.
Published: (2018-08-01)

Murine Fibroblasts and Primary Hepatocytes as Tools When Studying the Efficacy of Potential Therapies for Mucopolysaccharidosis Type I
by: Magdalena Węsierska, et al.
Published: (2022-12-01)

Mucopolysaccharidosis type III (subtype IIIB) diagnosis as a spectrum disorder: A case report from Kosovo
by: Lidvana Spahiu, et al.
Published: (2023-02-01)

Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
by: Alícia Dorneles Dornelles, et al.
Published: (2017-01-01)

Mucopolysaccharidosis Type 1 among Children—Neuroradiological Perspective Based on Single Centre Experience and Literature Review
by: Magdalena Machnikowska-Sokołowska, et al.
Published: (2023-01-01)